Non‐clinical Efficacy and Safety of SUVN‐L3307032, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM), for the Treatment of Neuropsychiatric Symptoms.
SUVN-L3307032 has the potential to be a new therapeutic option for the treatment of NPS associated with AD.
Authors
- Sravanthi Manchineella
- Tirumala Narasimhula
- Keerthi Sai Bitra
- Ramakrishna Nirogi (ORCID: https://orcid.org/0000-0002-2045-0784)
- Aamer Munaf Shaikh
- Rajesh Kumar Badange
- Kumar Bojja
- Rajesh Babu Medapati
- Venkatesh Goura
- Rajesh Kallepalli
- Onamala Varalakshmi
- Naga Sai Soma Chandra Sekhar Guduru
- Renny Abraham
- Kavya Sree Mukkollu
- Vinod Kumar Goyal
- Mary Praveena Nissankarao
- Santosh Kumar Pandey
- Ankit Das
Institutions
- Suven Life Sciences (India) (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_100081
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00